Abstract
Currently recommended boosted protease-inhibitor (bPI) regimens may be associated with increased risk of cardiovascular or chronic kidney diseases; in addition, boosted regimens are particularly associated with drug-drug interactions. Since both cardiovascular and renal disease, and polypharmacy, are common in ageing people with HIV, there is a need for alternative efficacious regimens. bPI-based regimens are often the treatment of choice for individuals with pre-treatment or treatment-acquired resistance but it is plausible that carefully selected HIV-positive individuals with drug resistance, who are virologically suppressed on their current bPI regimen, could maintain virological efficacy when switched to bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) fixed dose combination (FDC). A phase IV, investigator-initiated, multicentre, open label pilot, randomised two-arm study to assess the safety and efficacy of switching from bPI regimen to B/F/TAF single tablet regimen in integrase inhibitor-naïve, virologically suppressed adults with HIV-1 infection harbouring drug resistance mutations. Eligible individuals will either continue on their bPI regimen or switch to B/F/TAF FDC. After 24 weeks, all participants in t...Continue Reading
References
May 1, 1989·Psychiatry Research·D J BuysseD J Kupfer
Dec 26, 2001·Journal of Clinical Epidemiology·A C JusticeUNKNOWN Adult AIDS Clinical Trials Unit Outcomes Committee
Mar 19, 2002·Antimicrobial Agents and Chemotherapy·P R HarriganB A Larder
Oct 25, 2003·Antimicrobial Agents and Chemotherapy·Katharina WolfBarbara Schmidt
Nov 25, 2003·The New England Journal of Medicine·Nina Friis-MøllerUNKNOWN Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
Dec 3, 2003·The Journal of Antimicrobial Chemotherapy·Dan TurnerMark A Wainberg
Feb 21, 2004·The Journal of Infectious Diseases·Michael D MillerMichael Wulfsohn
Jan 16, 2010·Lancet·Joseph J EronUNKNOWN SWITCHMRK 1 and 2 investigators
Feb 23, 2012·AIDS Research and Human Retroviruses·Judith A AbergGuy De La Rosa
Mar 27, 2012·The Journal of Infectious Diseases·Kim C E SigaloffUNKNOWN PharmAccess African Studies to Evaluate Resistance (PASER)
May 23, 2012·AIDS Patient Care and STDs·E Jennifer EdelmanUNKNOWN Vacs Project Team
Jun 29, 2013·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Peter J RuaneKitty Yale
Oct 5, 2013·Health and Quality of Life Outcomes·Kit N SimpsonAlbert W Wu
Jul 12, 2014·The New England Journal of Medicine·Nicholas I PatonUNKNOWN EARNEST Trial Team
Oct 7, 2014·Annals of Internal Medicine·Jeffrey L LennoxUNKNOWN ACTG A5257 Team
Apr 1, 2015·PLoS Medicine·Amanda MocroftUNKNOWN ESPRIT study group
Jul 8, 2015·Antimicrobial Agents and Chemotherapy·Nicolas A MargotChristian Callebaut
Dec 8, 2015·Antiviral Research·Adrian S RayMichael J M Hitchcock
Aug 9, 2016·Nature Medicine·Katherine M BrunerRobert F Siliciano
Sep 21, 2016·Antimicrobial Agents and Chemotherapy·Manuel TsiangHaolun Jin
Oct 26, 2016·BMJ : British Medical Journal·Sandra M EldridgeUNKNOWN PAFS consensus group
Jun 2, 2017·The Lancet. HIV·Laura CiaffiUNKNOWN MOBIDIP study group
Nov 8, 2017·AIDS·José M GatellUNKNOWN NEAT022 Study Group*
Dec 13, 2017·Current Opinion in Infectious Diseases·Jens LundgrenLene Ryom
Dec 23, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alexander J StockdaleAnna Maria Geretti
May 8, 2018·The Lancet. HIV·Lene RyomUNKNOWN D:A:D study group
Jun 22, 2018·The Lancet. HIV·Eric S DaarErin Quirk
Jun 30, 2018·The Patient·David WohlErin Quirk